MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

long-term efficacy

Search medical newsFind research, conditions and clinical updates
  • Home
  • long-term efficacy
Three-Year Follow-Up of Lisocabtagene Maraleucel Demonstrates Durable Remission and Manageable Safety in Relapsed/Refractory Follicular Lymphoma
Posted inHematology-Oncology news Oncology

Three-Year Follow-Up of Lisocabtagene Maraleucel Demonstrates Durable Remission and Manageable Safety in Relapsed/Refractory Follicular Lymphoma

Posted by By MedXY 10/11/2026
Lisocabtagene maraleucel shows sustained high remission rates and a favorable long-term safety profile in patients with heavily pretreated follicular lymphoma after three years of follow-up, including high-risk subgroups.
Read More
Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis
Posted inGastroenterology news Specialties

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

Posted by By MedXY 08/14/2025
Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • The Global Physical Literacy (GloPL) Action Framework: Consensus Process and Practical Recommendations
  • Aligning Rehabilitation Priorities to Enhance Home and Work Functioning in Low Back Pain: Insights from a Stakeholder-Driven Group Concept Mapping Study
  • Enhancing Diagnostic Confidence in Endodontics: Patient Perspectives on Cone-Beam Computed Tomography and Radiation Awareness
  • Empirical Tuberculosis Treatment in Infants Living with HIV Hospitalised with Severe Pneumonia in Africa (EMPIRICAL): A Comprehensive Review of a Multicentre Randomised Controlled Trial
  • Elevated Mental Health Diagnosis Prevalence Among Children With Complex and Chronic Medical Conditions: Implications for Screening and Equity
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top